Combining eyelid pressure patching with AMT effectively heals persistent corneal epithelial defects, offering rapid ...

Rare eye diseases are the leading cause of untreatable blindness in Europe and affect people of all ages. The RESTORE VISION ...

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Glaukos (NYSE:GKOS) said the FDA has accepted its market application for its drug Epioxa for the treatment of the corneal ...

The Ocular Neurobiology laboratory at the Institute for Neurosciences, a joint center of Miguel Hernández University (UMH) in Elche and the Spanish ...

Glaukos (GKOS) announced it has received the “Day 74” notification from the U.S. Food and Drug Administration FDA acknowledging the previously ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and ...